Amicrobial Pustulosis of the Folds Successfully Treated With Apremilast: Report of Two Cases and Review of the Literature
The Journal of Dermatology · 2026-02 · 53 (2) · 339-350
DOI: 10.1111/1346-8138.70113 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, online erschienen am 15.12.2025. Verfasst von Luca Bettolini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Thalidomide, Phosphodiesterase 4 Inhibitors, Anti-Inflammatory Agents, Non-Steroidal, Skin Diseases, Vesiculobullous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Amicrobial pustulosis of the folds (APF) is a rare, chronic‐relapsing neutrophilic dermatosis characterized by sterile pustules affecting major and minor skin folds. It predominantly affects women and is frequently associated with autoimmune diseases such as systemic lupus erythematosus, inflammatory bowel disease, and autoimmune thyroiditis. Due to its rarity, standardized treatment guidelines are lacking, and management remains challenging. Systemic corticosteroids, dapsone, colchicine, methotrexate, and biologics have been employed with variable outcomes, but long‐term control is often difficult to achieve. Apremilast, an oral phosphodiesterase‐4 inhibitor with anti‐inflammatory properties, has demonstrated efficacy in various neutrophilic dermatoses. We report two women with treatment‐refractory APF who achieved clinical remission within 2 months of initiating apremilast, with sustained disease control at 6 months and successful corticosteroid tapering. A literature review of 78 APF cases confirmed a strong female predominance (93.6%) and frequent association with autoimmune conditions (91%). Systemic corticosteroids were the most frequently employed treatment but often failed to provide sustained disease control without the addition of other systemic agents. These cases represent the first reports of apremilast use in APF and suggest its potential as a safe and effective steroid‐sparing option in patients with refractory disease. Further studies are needed to validate its role in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
- Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
- Pathology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
ORCID-Profile: Luca Bettolini, Stefano Bighetti, Stefano Buffon, Angelo Valerio Marzano
Zitieren
APA
Bettolini, L., Maronese, C. A., Bighetti, S., Genovese, G., Sarno, L., Buffon, S., Boggio, F. L., Derlino, F., & Marzano, A. V. (2026). Amicrobial Pustulosis of the Folds Successfully Treated With Apremilast: Report of Two Cases and Review of the Literature. The Journal of Dermatology, 53(2), 339-350. https://doi.org/10.1111/1346-8138.70113
Vancouver
Bettolini L, Maronese CA, Bighetti S, Genovese G, Sarno L, Buffon S, et al. Amicrobial Pustulosis of the Folds Successfully Treated With Apremilast: Report of Two Cases and Review of the Literature. The Journal of Dermatology. 2026;53(2):339-350. doi:10.1111/1346-8138.70113
BibTeX
@article{Bettolini2026,
author = {Bettolini, Luca and Maronese, Carlo Alberto and Bighetti, Stefano and Genovese, Giovanni and Sarno, Luisa and Buffon, Stefano and Boggio, Francesca Laura and Derlino, Federica and Marzano, Angelo Valerio},
title = {Amicrobial Pustulosis of the Folds Successfully Treated With Apremilast: Report of Two Cases and Review of the Literature},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {2},
pages = {339--350},
doi = {10.1111/1346-8138.70113}
}
EUVIMED